Next Article in Journal
Nonsteroidal Anti-Inflammatory Drugs and the Kidney
Next Article in Special Issue
Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders
Previous Article in Journal
Emerging Families of Ion Channels Involved in Urinary Bladder Nociception
Previous Article in Special Issue
Linezolid Resistance in Staphylococci
Open AccessReview

Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery

Biodesign Institute Center for Infectious Diseases and Vaccinology, School of Life Sciences, Arizona State University, Tempe, AZ, 85287-5401, USA
Pharmaceuticals 2010, 3(7), 2268-2290;
Received: 15 June 2010 / Accepted: 19 July 2010 / Published: 20 July 2010
(This article belongs to the Special Issue Antibiotics)
Mycobacterium tuberculosis is an extraordinarily successful human pathogen, infecting one-third of the world’s population and causing nearly two million deaths each year. In this article, current trends in worldwide tuberculosis (TB) incidence, prevalence, and mortality are discussed along with standard TB treatment regimens, characteristics of first-line and second-line anti-tuberculosis drugs, and mechanisms of antibiotic resistance. The global TB emergency has been further exacerbated by extensively drug-resistant (XDR) TB strains that are resistant to our best antibiotics and very difficult to treat. This review also focuses on the emergence of XDR-TB strains, the global health impact, and existing treatment options and outcomes for XDR-TB disease. Finally, this review briefly describes new anti-tuberculosis drugs currently in Phase II clinical evaluations and the impetus for discovering new antibacterial compounds to target drug-resistant M. tuberculosis and improve tuberculosis therapy. View Full-Text
Keywords: tuberculosis; antimicrobial; drug; resistance tuberculosis; antimicrobial; drug; resistance
Show Figures

Figure 1

MDPI and ACS Style

Haydel, S.E. Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery. Pharmaceuticals 2010, 3, 2268-2290.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop